MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Ondansetron Hydrochloride 2.5 mg/mL Injection (Solution, 40 mL)	FIN	F 004 976

Note: Ondansetron Hydrochloride 2.5 mg/mL is equivalent to Ondansetron 2 mg/mL.

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Ondansetron Hydrochloride (Dihydrate), USP	0.100	g				
Sodium Chloride, USP	0.27	g				
Benzyl Alcohol, NF	0.4	mL				
Citric Acid (Monohydrate), USP	0.02	g				
Sodium Citrate (Dihydrate), USP	0.01	g				
Sterile Water for Injection, USP	30.0	mL				
Sterile Water for Injection, USP	q.s. to 40.0	mL				
Hydrochloric Acid 10% Solution	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive *(protect from light whenever possible):* *Ondansetron Hydrochloride (Dihydrate), Benzyl Alcohol*

Suggested Preparatory Guidelines

☐ Non-Sterile Preparation ■ Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Ondansetron Hydrochloride 2.5 mg/mL Injection (Solution, 40 mL)	FIN	F 004 976

SUGGESTED PREPARATION (for 40 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Ondansetron Hydrochloride (Dihydrate), USP §	0.100	g			
Sodium Chloride, USP §	0.27	g			
Benzyl Alcohol, NF §	0.4	mL			
Citric Acid (Monohydrate), USP §	0.02	g			
Sodium Citrate (Dihydrate), USP §	0.01	g			
Sterile Water for Injection, USP §	30.0	mL			
Sterile Water for Injection, USP §	q.s. to 40.0	mL			
Hydrochloric Acid 10% Solution §	As required				

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

Preparatory Instruction **IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique**	
1.	**Equipment sterilization:** Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.
2.	**Medium Integration:** A. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (30.0 mL *plus* processing error adjustments): -Benzyl Alcohol -Sodium Chloride -Citric Acid (Monohydrate) -Sodium Citrate (Dihydrate) -Ondansetron Hydrochloride (Dihydrate) Specifications: Continuously mix until all solid particles have completely dissolved. End result: Homogeneous liquid-like solution. Note: Add the next ingredient, once the previous one has been completely added and dissolved.

Suggested Formula	Ondansetron Hydrochloride 2.5 mg/mL Injection (Solution, 40 mL)	FIN	F 004 976

3.	**pH testing:** A. Draw an appropriate amount of the mixture (Step 2A). B. Test the pH of the sample. It should lie between 3.6 and 4.0. C. If the pH > 4.0, carefully add in a dropwise manner the Hydrochloric Acid 10% Solution to the mixture: 1. Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% Solution to the mixture. 2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% Solution. 3. Re-test the pH. 4. Continue to add the Hydrochloric Acid 10% Solution until the pH of 3.6 to 4.0 is obtained. IMPORTANT: Do not allow the pH to fall below 3.6.
4.	**Filling to volume:** A. Add additional Sterile Water For Injection to the above mixture to fill to the required batch size (40.0 mL *plus* processing error adjustments). Specifications: Continuously mix. End result: Homogeneous liquid-like solution.
5.	**Filtering and transferring:** Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.
6.	**Filter integrity test:** Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
7.	**Sterility testing:** Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

Suggested Formula	Ondansetron Hydrochloride 2.5 mg/mL Injection (Solution, 40 mL)	FIN	F 004 976

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		14 days, refrigerated, as per USP 797. BUD based on a successful sterility and endotoxin test result.	Packaging Requirements		Sterile, tightly closed, light-resistant unit-dose injection vials.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.		6	Discard container after use.
	2	Keep out of reach of children.		7	Protect from light.
	3	Keep refrigerated. Do not freeze.		8	Equilibrate to room temperature before use.
	4	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.		9	Discard in the presence of particulate matter.
	5	Do not use if product changes color.		10	Keep in a dry place.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.				
Patient Instructions	Contact your pharmacist in the event of adverse reactions.				

Suggested Formula	Ondansetron Hydrochloride 2.5 mg/mL Injection (Solution, 40 mL)	FIN	F 004 976

REFERENCES

1. Parenteral Preparations. In: Allen, LV, Jr. *The Art, Science and Technology of Pharmaceutical Compounding Third Edition.* American Pharmaceutical Association; 2008: 313.
2. Benzyl Alcohol. In: Rowe RC. *Handbook of Pharmaceutical Excipients, 6th Edition*. American Pharmaceutical Association; 2009: 64.
3. Ondansetron Hydrochloride. In: Sweetman SC, ed. *Martindale: The Complete Drug Reference, 36th Edition.* London, England: The Pharmaceutical Press; 2009: 1756.
4. Ondansetron (Monograph). In: O'Neil MJ. *The Merck Index 14th Edition.* Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #6848.
5. Ondansetron Hydrochloride. In: Trissel LA. *Trissel's Stability of Compounded Formulations, 3rd Edition.* American Pharmaceutical Association; 2005: 321.
6. Ondansetron Hydrochloride (Monograph). *United States Pharmacopeia XXXIV / National Formulary 29.* Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 3722.
7. Ondansetron. Thomson Micromedex. *USP DI – Drug Information for the Health Care Professional, 26th Edition.* Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2257.
8. Chapter 8: Buffered and Isotonic Solutions. In: Martin, A. *Physical Pharmacy, Fourth Edition.* Philadelphia, PA: Lipponcott Williams & Wilkins; 1993: 169~189.
9. Chapter 18: Tonicity, Osmoticity, Osmolaltiy and Osmolarity. In: D.B Troy. *Remington: The Science and Practice of Pharmacy, 21st Edition.* Baltimore, MD: Lippincott Williams & Wilkins; 2006: 250~265
10. USP <797>. *United States Pharmacopeia XXXIV / National Formulary 29.* Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 336.